GLP's ⏱ Half-life: Approximately 5 days (120 hours), supporting once-weekly administration. Steady-state concentrations reached in 4-5 weeks.

Tirzepatide

Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)

Buy from $109.99 →
Half-Life
Approximately 5 days (120 hours), supporting once-weekly administration. Steady-state concentrations reached in 4-5 weeks.
Mol. Weight
4813.45 g/mol

What is Tirzepatide?

Tirzepatide represents a novel approach in metabolic peptide research as the first dual GIP/GLP-1 receptor agonist. By simultaneously activating both incretin hormone receptors, it engages complementary metabolic pathways that appear to produce synergistic effects beyond what either receptor alone can achieve.

The compound has generated significant research interest due to clinical trial results showing superior metabolic outcomes compared to selective GLP-1 receptor agonists, challenging assumptions about optimal approaches to metabolic peptide research.

Research Applications

Major clinical research programs include:

  • SURPASS trials: Head-to-head comparison with existing GLP-1 agonists for glycemic outcomes
  • SURMOUNT trials: Body composition research at higher dose levels
  • Cardiovascular: SURPASS-CVOT examining major cardiac event outcomes
  • Sleep apnea: Research into respiratory-related sleep disorder improvement
  • MASH/NASH: Liver fat and fibrosis studies

Dosage Information (Research Use)

Published clinical titration protocols:

  • Starting dose: 2.5 mg once weekly for 4 weeks
  • Titration steps: 2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0 mg
  • Escalation interval: 4 weeks minimum at each dose level
  • Administration: Once weekly, subcutaneous

Research compound. See published SURPASS and SURMOUNT trial protocols for detailed methodology.

Reconstitution & Handling

Similar reconstitution protocol to semaglutide. Dissolve slowly with BAC water, roll gently, and protect from light.

Half-Life & Pharmacokinetics

Approximately 5 days (120 hours), supporting once-weekly administration. Steady-state concentrations reached in 4-5 weeks.

Reported Observations in Literature

Clinical trial data shows a similar GI observation profile to GLP-1 agonists: nausea, diarrhea, vomiting — mostly mild-to-moderate and transient with proper titration. Reduced injection site reactions compared to some GLP-1 comparators in published data.

Key Research References

  • Frias JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” N Engl J Med. 2021 (SURPASS-2)
  • Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022 (SURMOUNT-1)

How Tirzepatide Works

Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. It has 5:1 GIP-to-GLP-1 receptor affinity. The dual mechanism engages complementary metabolic pathways: GIP receptor activation enhances insulin secretion, improves lipid metabolism, and may directly affect adipose tissue. GLP-1 receptor activation provides glucose-dependent insulin secretion, glucagon suppression, and appetite regulation. The combined effect appears synergistic rather than additive. A C20 fatty diacid chain enables albumin binding for extended half-life.

Research Findings

Head-to-head clinical trials (SURPASS program) have shown superior glycemic and weight outcomes compared to semaglutide 1mg. The SURMOUNT program examined body composition effects at doses up to 15mg weekly. Mechanistically notable for challenging previous assumptions about GIP's role in metabolic regulation — historically considered counter-therapeutic, the dual agonism approach has shown unexpected efficacy.

Dosage & Administration

Published clinical titration protocols:

  • Starting dose: 2.5 mg once weekly for 4 weeks
  • Titration steps: 2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0 mg
  • Escalation interval: 4 weeks minimum at each dose level
  • Administration: Once weekly, subcutaneous

Research compound. See published SURPASS and SURMOUNT trial protocols for detailed methodology.

Safety & Side Effects

Clinical trial data shows a similar GI observation profile to GLP-1 agonists: nausea, diarrhea, vomiting — mostly mild-to-moderate and transient with proper titration. Reduced injection site reactions compared to some GLP-1 comparators in published data.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence 39-amino acid peptide with C20 fatty diacid moiety
Molecular Weight 4813.45 g/mol
Half-Life Approximately 5 days (120 hours), supporting once-weekly administration. Steady-state concentrations reached in 4-5 weeks.
Available Sizes 5mg, 10mg, 15mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, protect from light, use within 28 days.

Key Research References

  • Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021 (SURPASS-2)
  • Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022 (SURMOUNT-1)

Get Tirzepatide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Dulaglutide
GLP's
FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, administered once weekly.
View Profile → Buy at SP →
Lixisenatide
GLP's
FDA-approved short-acting GLP-1 receptor agonist with unique postprandial glucose control properties.
View Profile → Buy at SP →
Pramlintide
GLP's
FDA-approved synthetic amylin analog that complements insulin therapy by slowing gastric emptying, reducing glucagon, and enhancing satiety.
View Profile → Buy at SP →